315 related articles for article (PubMed ID: 25763355)
1. Phenotype switching in melanoma: implications for progression and therapy.
Li FZ; Dhillon AS; Anderson RL; McArthur G; Ferrao PT
Front Oncol; 2015; 5():31. PubMed ID: 25763355
[TBL] [Abstract][Full Text] [Related]
2. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines.
Noguchi K; Dalton AC; Howley BV; McCall BJ; Yoshida A; Diehl JA; Howe PH
PLoS One; 2017; 12(5):e0177830. PubMed ID: 28545079
[TBL] [Abstract][Full Text] [Related]
4. Tracking the EMT-like phenotype switching during targeted therapy in melanoma by analyzing extracellular vesicle phenotypes.
Zhou Q; Wang J; Zhang Z; Wuethrich A; Lobb RJ; Trau M
Biosens Bioelectron; 2024 Jan; 244():115819. PubMed ID: 37952322
[TBL] [Abstract][Full Text] [Related]
5. NK-cell Editing Mediates Epithelial-to-Mesenchymal Transition via Phenotypic and Proteomic Changes in Melanoma Cell Lines.
Huergo-Zapico L; Parodi M; Cantoni C; Lavarello C; Fernández-Martínez JL; Petretto A; DeAndrés-Galiana EJ; Balsamo M; López-Soto A; Pietra G; Bugatti M; Munari E; Marconi M; Mingari MC; Vermi W; Moretta L; González S; Vitale M
Cancer Res; 2018 Jul; 78(14):3913-3925. PubMed ID: 29752261
[TBL] [Abstract][Full Text] [Related]
6. EMT-Inducing Transcription Factors, Drivers of Melanoma Phenotype Switching, and Resistance to Treatment.
Tang Y; Durand S; Dalle S; Caramel J
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32759677
[TBL] [Abstract][Full Text] [Related]
7. Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.
Pearlman RL; Montes de Oca MK; Pal HC; Afaq F
Cancer Lett; 2017 Apr; 391():125-140. PubMed ID: 28131904
[TBL] [Abstract][Full Text] [Related]
8. ROR2, a driver of "phenotype switching" in melanoma?
Lopez-Bergami P
Cancer Cell Int; 2022 Sep; 22(1):288. PubMed ID: 36127680
[TBL] [Abstract][Full Text] [Related]
9. Diverse pathways of epithelial mesenchymal transition related with cancer progression and metastasis and potential effects of endocrine disrupting chemicals on epithelial mesenchymal transition process.
Lee HM; Hwang KA; Choi KC
Mol Cell Endocrinol; 2017 Dec; 457():103-113. PubMed ID: 28042023
[TBL] [Abstract][Full Text] [Related]
10. Melanoma cells revive an embryonic transcriptional network to dictate phenotypic heterogeneity.
Vandamme N; Berx G
Front Oncol; 2014; 4():352. PubMed ID: 25538895
[TBL] [Abstract][Full Text] [Related]
11. PI3K signalling is required for a TGFβ-induced epithelial-mesenchymal-like transition (EMT-like) in human melanoma cells.
Schlegel NC; von Planta A; Widmer DS; Dummer R; Christofori G
Exp Dermatol; 2015 Jan; 24(1):22-8. PubMed ID: 25363503
[TBL] [Abstract][Full Text] [Related]
12. Melanoma cell-derived exosomes promote epithelial-mesenchymal transition in primary melanocytes through paracrine/autocrine signaling in the tumor microenvironment.
Xiao D; Barry S; Kmetz D; Egger M; Pan J; Rai SN; Qu J; McMasters KM; Hao H
Cancer Lett; 2016 Jul; 376(2):318-27. PubMed ID: 27063098
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic Balance between ZEB Family Members Is Important for Melanocyte Homeostasis and Melanoma Progression.
Bruneel K; Verstappe J; Vandamme N; Berx G
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32796736
[TBL] [Abstract][Full Text] [Related]
14. Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance.
Hossain SM; Eccles MR
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675114
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-to-mesenchymal transition in tumor progression.
Prieto-García E; Díaz-García CV; García-Ruiz I; Agulló-Ortuño MT
Med Oncol; 2017 Jul; 34(7):122. PubMed ID: 28560682
[TBL] [Abstract][Full Text] [Related]
16. Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells.
Woods K; Pasam A; Jayachandran A; Andrews MC; Cebon J
Front Oncol; 2014; 4():367. PubMed ID: 25566505
[TBL] [Abstract][Full Text] [Related]
17. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
18. Fibronectin 1 promotes melanoma proliferation and metastasis by inhibiting apoptosis and regulating EMT.
Li B; Shen W; Peng H; Li Y; Chen F; Zheng L; Xu J; Jia L
Onco Targets Ther; 2019; 12():3207-3221. PubMed ID: 31118673
[No Abstract] [Full Text] [Related]
19. Translational Significance for Tumor Metastasis of Tumor-Associated Macrophages and Epithelial-Mesenchymal Transition.
Song W; Mazzieri R; Yang T; Gobe GC
Front Immunol; 2017; 8():1106. PubMed ID: 28955335
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma.
Mir N; Jayachandran A; Dhungel B; Shrestha R; Steel JC
Curr Cancer Drug Targets; 2017; 17(8):698-706. PubMed ID: 28460616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
